Genetic Signatures and Microba in Merger Discussions

Key points

• Genetic Signatures and Microba are in merger discussions.
• The merger aims to create a leading infectious disease diagnostics group.
• The combined group would have FY2026 revenue of approximately A$29 million.

Full summary

Genetic Signatures Limited (ASX: GSS) is in discussions with Microba Life Sciences Limited (ASX: MAP) about combining the two businesses to create a leading, scalable ASX-listed infectious disease diagnostics group. The merger would provide broader access to major pathology networks, a differentiated infectious-disease offering, and further establish Genetic Signatures' domestic and international footprint. The combined group would have FY2026 revenue of approximately A$29 million and combined cash and term deposits of approximately A$30 million as at 30 June 2026. The discussions are presently at a preliminary stage and remain incomplete.

Guidance

FY2026 revenue of approximately A$29 million

Outlook

The merger aims to create a leading infectious disease diagnostics group with broader market access and a stronger balance sheet.